crenauer

Cory Renauer

Cory is a long-term minded analyst mainly focused on the biotechnology and pharmaceuticals. He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. He's a husband and father that is always up for just about any outdoor activity. You can contact Cory on Twitter @coryrenauer

crenauer’s Activity

Fri Feb 5

Caps Pick

crenauer made a pick in CAPS. 3:39 PM

Vertex Pharmaceuticals (VRTX) will Outperform the S&P 500
NL

Article

crenauer published an article 12:41 PM

Can NewLink Genetics Win the Zika Vaccine Race?

Does NewLink's success with Ebola suggest it can do the same with Zika?

Fri Jan 29

NL

Article

crenauer published an article 3:51 PM

3 Potential Blockbusters Moving the Needle for Big Pharma in 2016

These pharmas have some recently approved drugs that could singlehandedly boost total sales this year.

Wed Jan 27

NL

Article

crenauer published an article 2:30 PM

Will AmerisourceBergen Raise Its Dividend in 2016?

After paying for an important alliance, another big dividend boost is questionable.

Mon Jan 25

NL

Article

crenauer published an article 3:13 PM

Start the New Year off Right with 3 Best Biotech Stocks

2016 has been rough so far on biotech -- but owners of these three stocks need not worry.

Wed Jan 20

NL

Article

crenauer published an article 6:16 PM

Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks

Find out where some investors might find better dividend growth opportunities.

Tue Jan 19

NL

Article

crenauer published an article 7:19 AM

What If Medicare Had Teeth?

See how much some drugmakers could lose if Medicare pegged drug price increases to inflation.

Mon Jan 18

NL

Article

crenauer published an article 12:04 PM

Will 2016 Be Vertex's Best Year Yet?

It's shaping up to be a banner year for the cystic fibrosis leader.

Fri Jan 8

NL

Article

crenauer published an article 5:07 PM

Gilead Sciences Takes 2 Steps Forward and 1 Step Back

Gilead's antiviral segment gets even stronger, but expansion into other fields remains elusive.

Wed Jan 6

NL

Article

crenauer published an article 4:14 PM

3 Biotechs With Major Catalysts Incoming

Up or down, these three stocks are about to move. Here's what you need to know.

Wed Dec 23

NL

Article

crenauer published an article 3:22 AM

Drugmaker Returns on R&D Are Shrinking

Find out which companies are bucking the trend -- and why.

Tue Dec 22

NL

Article

crenauer published an article 3:07 AM

Can Gilead Sciences Score With AbbVie's Dropped Ball?

Galapagos has a potential blockbuster in filgotinib, no matter who helps develop it.

Fri Dec 18

NL

Article

crenauer published an article 1:33 PM

Big Firms Love This Little Biotech

Should retail investors follow?

Wed Dec 16

NL

Article

crenauer published an article 12:23 PM

3 New Drugs Ready to Explode in 2016

These three little pills are about to make a big splash.

Thu Dec 10

NL

Article

crenauer published an article 3:46 PM

Can AbbVie's New Cancer Drugs Offset Humira Losses?

Expansion of Imbruvica and potential approval of venetoclax could keep AbbVie's top line from falling off a patent cliff.

Tue Dec 8

NL

Article

crenauer published an article 12:36 PM

What's Next for bluebird bio?

No longer considered a cure-for-all, bluebird bio makes some changes to its LentiGlobin program.

Mon Dec 7

Caps Pick

crenauer made a pick in CAPS. 12:53 PM

Bluebird Bio (BLUE) will Outperform the S&P 500

Fri Dec 4

NL

Article

crenauer published an article 3:08 PM

Do Eli Lilly and Biogen Have Alzheimer's All Wrong? Anavex Life Sciences Thinks So.

Anavex Life Sciences could soon have the data to prove that there's a better way to approach fighting Alzheimer's.

Thu Dec 3

NL

Article

crenauer published an article 9:04 AM

Can AstraZeneca Live Up to Its $45 Billion Promise?

A robust late-stage pipeline might be enough to stop revenue from sliding, but reaching $45 billion in sales by 2023 is another story.

Tue Dec 1

NL

Article

crenauer published an article 4:05 PM

Bristol-Myers Squibb Finally Hits a Roadblock

After five successful label expansions in less than a year, the FDA finally issues a denial for this immuno-oncology superstar.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 61.97
Player Rank 28480 out of 74891
Score 108.30
Score Change Today -10.33
Accuracy 51.95%
Active Picks 14
Total Picks 84
Best Pick NPSP.DL (+169.80)
Worst Pick NSPH (-121.59)
Average Score per Pick 1.30
Charms Earned 2
Highest Rated Favorite TMFBiologyFool
Go to crenauer’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show crenauer’s 10 Latest Posts